Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 5Phase 3 4Phase 1/2 3

Status

Completed 25Recruiting 7Terminated 5Withdrawn 4Unknown 3Active not recruiting 3Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 2Graft vs Host Disease 2Waldenstrom Macroglobulinemia 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Hematologic Neoplasms 1Anemia, Aplastic 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Sirolimus × Clear all
NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
35 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT03983850 2025-12-26

Optimizing PTCy Dose and Timing

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
105 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT03225417 2024-08-30

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 1/2 Active not recruiting
142 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡